Inflammation

, Volume 35, Issue 3, pp 1138–1143

The Efficiency of a Urotensin II Antagonist in an Experimental Lung Fibrosis Model

  • Ahmet Mesut Onat
  • Ibrahim Halil Turkbeyler
  • Yavuz Pehlivan
  • Tuncer Demir
  • Davut Sinan Kaplan
  • Seyithan Taysi
  • Ali Osman Ceribasi
  • Ediz Tutar
  • Bunyamin Kisacik
Article

Abstract

Pulmonary fibrosis is a chronic disease. Urotensin II (U-II) is a new peptide with angiogenic and profibrotic features. Therefore, we aim to evaluate the antagonism of U-II with palosuran in an animal model and plan to measure U-II, endothelin-1 (ET-1), and transforming growth factor-β1 (TGF-β1) and their association with lung fibrosis. Thirty Wistar male rats were used in the study and were divided into three groups: group 1, control; group 2, bleomycin-induced lung fibrosis group; and group 3, bleomycin-induced lung fibrosis with treatment palosuran group. U-II level (nanograms per milliliter) was 2.957 ± 0.159 in group1, 3.188 ± 0.122 in group 2, and 2.970 ± 0.165 in group 3 (p = 0.002). The ET-1 level (picograms per milliliter) was 4.486 ± 0.376 in group 1, 9.086 ± 1.850 in group 2, and 4.486 ± 0.376 in group 3 (p < 0.001). The TGF-β1 (nanograms per milliliter) level was 73.143 ± 9.96 in group 1, 84.81 ± 4.73 in group 2, and 77.86 ± 5.77 in group 3 (p = 0.006). Finally, the fibrosis score was 0.7 ± 0.48 in group 1, 4.4 ± 1.34 in group 2, and 3.2 ± 0.63 in group 3 (p < 0.001). There is a statistically significant positive relationship between fibrosis scores and the UT-II, ET-1, and TGF-β1 levels of the experimental lung fibrosis model. We believe U-II is an important mediator in lung fibrosis models, and its antagonism with palosuran could be a new treatment choice for interstitial lung fibrosis, but further studies need to be conducted to verify the findings of the current study.

KEY WORDS

lung fibrosis endothelin-1 urotensin II antagonist palosuran 

REFERENCES

  1. 1.
    Cook, D.N., D.M. Brass, and D.A. Schwartz. 2002. A matrix for new ideas in pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology 27: 122–1244.PubMedGoogle Scholar
  2. 2.
    Ozyurt, H., S. Söğüt, Z. Yildirim, L. Kart, M. Iraz, F. Armutçu, I. Temel, S. Ozen, A. Uzun, and O. Akyol. 2004. Inhibitory effect of caffeic acid phenethyl ester (cape) on bleomycine-induced lung fibrosis in rats. Clinica Chimica Acta 339: 65–75.CrossRefGoogle Scholar
  3. 3.
    Daniil, Z.D., F.C. Gilchrist, A.G. Nicholson, D.M. Hansell, J. Harris, T.V. Colby, and R.M. du Bois. 1999. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. American Journal of Respiratory and Critical Care Medicine 160: 899–905.PubMedGoogle Scholar
  4. 4.
    Mason, R.J., M.I. Schwarz, G.W. Hunninghake, and R.A. Musson. 1999. NHLBI Workshop Summary. Pharmacological therapy for idiopathic pulmonary fibrosis. Past, present, and future. American Journal of Respiratory and Critical Care Medicine 160: 1771–1777.PubMedGoogle Scholar
  5. 5.
    Park, S.H., D. Saleh, A. Giaid, and R.P. Michel. 1997. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. American Journal of Respiratory and Critical Care Medicine 156: 600–608.PubMedGoogle Scholar
  6. 6.
    King Jr., T.E., J. Behr, K.K. Brown, R.M. du Bois, L. Lancaster, J.A. de Andrade, G. Stähler, I. Leconte, S. Roux, and G. Raghu. 2008. BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 177: 75–81.PubMedCrossRefGoogle Scholar
  7. 7.
    Coulouarn, Y., I. Lihrmann, S. Jegou, Y. Anouar, H. Tostivint, J.C. Beauvillain, J.M. Conlon, H.A. Bern, and H. Vaudry. 1998. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proceedings of the National Academy of Sciences of the United States of America 95: 15803–15808.PubMedCrossRefGoogle Scholar
  8. 8.
    Wang, H., J.L. Mehta, K. Chen, X. Zhang, and D. Li. 2004. Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. Journal of Cardiovascular Pharmacology 44: 577–581.PubMedCrossRefGoogle Scholar
  9. 9.
    Tran, L., A.R. Kompa, W. Kemp, A. Phrommintikul, B.H. Wang, and H. Krum. 2010. Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats. American Journal of Physiology. Heart and Circulatory Physiology 298: 608–613.CrossRefGoogle Scholar
  10. 10.
    Pehlivan, Y., A.M. Onat, G. Comez, and T. Babacan. 2001. Urotensin-II in systemic sclerosis: A new peptide in pathogenesis. Clinical Rheumatology 28. Epub ahead of print.Google Scholar
  11. 11.
    Pehlivan, Y., B. Gogebakan, S. Oztuzcu, M. Ozgen, G.Y. Cetin, R. Bayraktar, B. Cengiz, B. Kisacik, S.S. Koca, S. Donmez, M. Sayarlioglu, A.T. Demiryurek, and A. M. Onat. 2011. Association between Thr21Met and Ser89Asn polymorphisms of the urotensin II gene and systemic sclerosis. J Rheumatol Nov 1. (In press).Google Scholar
  12. 12.
    Sidharta, P.N., P.L. van Giersbergen, and J. Dingemanse. 2009. Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjects. Journal of Clinical Pharmacology 49: 1168–1175.PubMedCrossRefGoogle Scholar
  13. 13.
    Chen, L., T. Wang, X. Wang, B.B. Sun, J.Q. Li, D.S. Liu, S.F. Zhang, L. Liu, D. Xu, Y.J. Chen, and F.Q. Wen. 2009. Blockade of advanced glycation end product formation attenuates bleomycin-induced pulmonary fibrosis in rats. Respiratory Research 10: 55.PubMedCrossRefGoogle Scholar
  14. 14.
    Clozel, M., P. Hess, C. Qiu, S.S. Ding, and M. Rey. 2006. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. Journal of Pharmacology and Experimental Therapeutics 316: 1115–1121.PubMedCrossRefGoogle Scholar
  15. 15.
    Ashcroft, T., J.M. Simpson, and V. Timbrell. 1988. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. Journal of Clinical Pathology 41: 467–470.PubMedCrossRefGoogle Scholar
  16. 16.
    Society, A.T. 2009. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). American Journal of Respiratory and Critical Care Medicine 161: 646–664.Google Scholar
  17. 17.
    Broekelmann, T.J., A.H. Limper, T.V. Colby, and J.A. McDonald. 1991. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proceedings of the National Academy of Sciences of the United States of America 88: 6642–6646.PubMedCrossRefGoogle Scholar
  18. 18.
    Atamas, S.P., and B. White. 2003. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine & Growth Factor Reviews 14: 537–550.CrossRefGoogle Scholar
  19. 19.
    Whyte, M., R. Hubbard, R. Meliconi, M. Whidborne, V. Eaton, C. Bingle, J. Timms, G. Duff, A. Facchini, A. Pacilli, M. Fabbri, I. Hall, J. Britton, I. Johnston, and F. Di Giovine. 2000. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. American Journal of Respiratory and Critical Care Medicine 162: 755–758.PubMedGoogle Scholar
  20. 20.
    Jiang, D., J. Liang, J. Hodge, B. Lu, Z. Zhu, S. Yu, J. Fan, Y. Gao, Z. Yin, R. Homer, C. Gerard, and P.W. Noble. 2004. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. The Journal of Clinical Investigation 114: 291–299.PubMedGoogle Scholar
  21. 21.
    Raghu, G., K.K. Brown, W.Z. Bradford, K. Starko, P.W. Noble, D.A. Schwartz, and T.E. King Jr. 2004. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. The New England Journal of Medicine 350: 125–133.PubMedCrossRefGoogle Scholar
  22. 22.
    Meadors, M., J. Floyd, and M.C. Perry. 2006. Pulmonary toxicity of chemotherapy. Seminars in Oncology 33: 98–105.PubMedCrossRefGoogle Scholar
  23. 23.
    Sleijfer, S. 2001. Bleomycin-induced pneumonitis. Chest 120: 617–624.PubMedCrossRefGoogle Scholar
  24. 24.
    Chandler, D.B., J.C. Barton, D.D. Briggs, T.W. Butler, J.I. Kennedy, W.E. Grizzle, and J.D. Fulmer. 1988. Effect of iron deficiency on bleomycin-induced lung fibrosis in the hamster. American Review of Respiratory Disease 137: 85–89.PubMedCrossRefGoogle Scholar
  25. 25.
    Douglas, S.A., A.C. Sulpizio, V. Piercy, H.M. Sarau, R.S. Ames, N.V. Aiyar, E.H. Ohlstein, and R.N. Willette. 2000. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. British Journal of Pharmacology 131: 1262–1274.PubMedCrossRefGoogle Scholar
  26. 26.
    Cosenzi, A. 2008. Non peptidic urotensin II antagonists: Perspectives for a new class of drugs. Cardiovascular & Hematological Agents in Medicinal Chemistry 6: 80–91.CrossRefGoogle Scholar
  27. 27.
    Bousette, N., J. Pottinger, W. Ramli, E.H. Ohlstein, D. Dhanak, S.A. Douglas, and A. Giaid. 2006. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27: 2919–2926.PubMedCrossRefGoogle Scholar
  28. 28.
    Simpson, C.M., J.J. Smolich, L.S. Shekerdemian, and D.J. Penny. 2010. Urotensin-II contributes to pulmonary vasoconstriction in a perinatal model of persistent pulmonary hypertension of the newborn secondary to meconium aspiration syndrome. Pediatric Research 67: 150–157.PubMedCrossRefGoogle Scholar
  29. 29.
    Trebicka, J., L. Leifeld, M. Hennenberg, E. Biecker, A. Eckhardt, N. Fischer, A.S. Pröbsting, C. Clemens, F. Lammert, T. Sauerbruch, and J. Heller. 2008. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. Hepatology 47: 1264–1276.PubMedCrossRefGoogle Scholar
  30. 30.
    Tian, L., C. Li, J. Qi, P. Fu, X. Yu, X. Li, and L. Cai. 2008. Diabetes-induced upregulation of UII and plays an important role in TGF-beta1-mediated renal fibrosis and dysfunction. American Journal of Physiology. Endocrinology and Metabolism 295: 1234–1242.CrossRefGoogle Scholar
  31. 31.
    Sidharta, P.N., F.D. Wagner, H. Bohnemeier, A. Jungnik, A. Halabi, S. Krähenbühl, H. Chadha-Boreham, and J. Dingemanse. 2006. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clinical Pharmacology and Therapeutics 80: 246–256.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ahmet Mesut Onat
    • 1
  • Ibrahim Halil Turkbeyler
    • 2
  • Yavuz Pehlivan
    • 1
    • 3
  • Tuncer Demir
    • 4
  • Davut Sinan Kaplan
    • 4
  • Seyithan Taysi
    • 5
  • Ali Osman Ceribasi
    • 6
  • Ediz Tutar
    • 7
  • Bunyamin Kisacik
    • 1
  1. 1.Department of Rheumatology, Sahinbey Medical Center, School of MedicineGaziantep UniversityGaziantepTurkey
  2. 2.Department of Internal Medicine, Sahinbey Medical Center, School of MedicineGaziantep UniversityGaziantepTurkey
  3. 3.Department of Rheumatology, Sahinbey Medical Center, School of MedicineGaziantep UniversityGaziantepTurkey
  4. 4.Department of Physiology, School of MedicineGaziantep UniversityGaziantepTurkey
  5. 5.Department of Biochemistry, School of MedicineGaziantep UniversityGaziantepTurkey
  6. 6.Department of Pathology, School of VeterinaryFirat UniversityElazigTurkey
  7. 7.Department of Pathology, School of MedicineGaziantep UniversityGaziantepTurkey

Personalised recommendations